[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hektoen Institute for Medical Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100504458","keeping-it-lite-exploring-hiv-risk-in-vulnerable-youth-with-limited-interaction-and-digital-health-intervention-100504458",false,"NCT05848570","Keeping it LITE: Exploring HIV Risk in Vulnerable Youth With Limited Interaction and Digital Health Intervention","LITE-2","Inclusion Criteria:\n\n* For young adults ages 18-34: self-identified SGM young adults ages 18-34 who meet at least one of the following criteria:\n\n  * 1\\) condomless anal or vaginal intercourse (CAI) with a cisgender man in the last 6 months OR\n  * 2\\) sex with cisgender men and bacterial STI in the last 6 months OR\n  * 3\\) anal or vaginal sex with a known HIV-infected partner in the last 6 months.\n* For adolescents 13-17: self-identified SGM adolescents ages 13-17 who have engaged in any sexual activity (e.g., oral, anal or vaginal sex)\n\nExclusion Criteria:\n\n* under age 13\n* over age 34",true,"ALL","13 Years","34 Years",{"count":21,"type":22},6000,"ESTIMATED","OBSERVATIONAL","Despite advances in HIV diagnostics, care and prevention strategies, infection rates among adolescent and young adult sexual and gender minorities (SGM) continue to rise in the United States (US). There is an urgent need to describe the epidemiology and trajectories of HIV acquisition in this population and to offer age and culturally appropriate scalable prevention interventions to those at highest risk of infection in the US. This project will engage and retain young SGM in an innovative longitudinal cohort, enroll participants in a dynamic established digital health retention platform (HMP; HealthMPowerment), monitor HIV risk and prevention behaviors and explore the socioecological factors that influence the use of new HIV prevention technologies (UG3 phase), while also allowing targeted testing of novel digital health interventions (UH3 phase). In Aim 1, the investigators will enroll and retain a large (n=6000; 3000\u002Fyear), diverse cohort of sexually active, SGM adolescents and young adults, ages 13-34, using innovative digital recruitment, engagement and retention strategies. Over the course of the study, the investigators will longitudinally characterize the sexual behavior, HIV transmission risk, and PrEP uptake trajectories of SGM youth utilizing epidemiological trajectory analyses to identify the most effective points of intervention (Aim 2). This study will capitalize upon productive existing partnerships and digital health expertise to articulate the drivers of the ongoing HIV epidemic among the most vulnerable populations in the US in order to identify the most effective, expeditious and scalable strategies to address this ongoing public health crisis.",[26,27],"HIV Infections","Sexual Behavior","RECRUITING","2023-04-27",{"date":31,"type":32},"2023-05-08","ACTUAL",{"date":34,"type":32},"2023-03-23",{"date":36,"type":22},"2027-05",{"name":38,"class":39},"Hektoen Institute for Medical Research","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":16,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100277468","feasibility-of-an-ingestible-sensor-system-to-measure-prep-adherence-in-ymsm-100277468","NCT02891720","Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM","Inclusion Criteria\n\nYoung men who meet all of the following criteria are eligible for inclusion:\n\n* PrEP-eligible YMSM\n* Ages 18-24\n* Biologically born male\n* Report interest in PrEP\n* Intend to use PrEP for a full 6 month period\n* Eligible to be a PrEP patient at the CORE Center PrEP Clinic\n* Meet one the following sexual risk criteria:\n\n  * Have an HIV-positive sexual partner\n  * Had recent bacterial STI\n  * Report high numbers of sexual partners\n  * Report history of inconsistent or no condom use\n  * Report exchange\u002Ftransactional sex.\n\nExclusion Criteria\n\nYoung men who meet any of the following criteria will be excluded:\n\n* HIV+\n* Creatinine clearance \\\u003C60 cc\u002Fmin)\n* Allergy to topical adhesive\n* Acute gastrointestinal symptoms\n* History of major GI surgery\n* Presence of an implanted electronic medical device.\n* Subjects who are receiving any of the following medications:Nephrotoxic drugs (e.g., cidofovir, amphotericin, aminoglycosides, dapsone, tacrolimus, foscarnet, ACE inhibitors), all diuretics, drugs that may interfere with TFV excretion (e.g., (Val)ganciclovir, Cyclosporin A, Sirolimus, Antineoplastics), drugs (not including mineral and vitamin supplements) used for treatment of osteoporosis (e.g., alendronate and other bisphosphonates, teriparatide, denosumab, and calcitonin), chronic use of oral or systemic steroids (i.e., daily use for two weeks or more is not allowed), experimental medications that are not Food and Drug Administration (FDA)-approved, and FTC\u002FTDF (Truvada®) received outside of the study","MALE","18 Years","24 Years",{"count":51,"type":22},100,"INTERVENTIONAL",[54],"NA","The goal of this study is to evaluate an integrated technology system that confirms ingestion of oral PrEP, monitors adherence both in real-time and longitudinally, and provides visual feedback mechanisms to promote enhanced adherence behaviors.",[57],"Human Immunodeficiency Virus","NOT_YET_RECRUITING","2016-09-01",{"date":61,"type":22},"2016-09-07",{"date":63,"type":4},"2017-06",{"date":65,"type":22},"2019-11",{"name":38,"class":39},""]